The first vaccines in the U.S. have now left the Pfizer facility and are on their way to all 50 states.

Two main trucks left on Sunday morning -- an additional truck will come in later to pick up a few boxes and take them to the U.S. territories.

On Monday Pfizer has an order for another 400 boxes of the vaccine as well as an order for a slightly less amount of boxes on Tuesday, the company said.

The first shipments are expected to arrive at 145 sites on Monday, 425 sites on Tuesday and another 66 sites on Wednesday, Gen. Gus Perna of the Trump administration's Operation Warp Speed vaccine program said.

At those sites, the vaccines will be paired with ancillary kits to assist with the vaccinations. The kits contain needles, syringes, alcohol swabs, diluent, safety gear and vaccine reminder cards.

-ABC News' Joshua Hoyos and Luis Martinez

FedEx has begun its shipment process of the Pfizer vaccine in the U.S. on Sunday morning, the company posted on Twitter.

Starting Wednesday, Dec. 16 through Jan. 10, all non-essential stores and schools will be closed in Germany and social meetings will be limited to five people from two households, with an exception made for the Christmas period from Dec. 24 to Dec. 26 when four more people beyond a household will be allowed.

No exceptions will be made for New Year's Eve.

COVID-19 transmissions remain high in the country despite softer restrictions in place. As of Dec. 13, the Robert Koch Institute reported a total of 20,2000 new cases and 321 deaths, bringing the totals to 1,320,716 and 21,787, respectively.

Germany had initially planned for a "semi-lockdown," allowing for a holiday exemption from Dec. 23 to Jan 1 where up to 10 people from two households could meet but those plans were scrapped in favor of these new rules.

ABC News' Christine Theodorou contributed to this report.

At least 16,062,299 Americans have been diagnosed with coronavirus, according to the latest data compiled by Johns Hopkins University.

There are currently over 108,000 Americans hospitalized with COVID-19 nationwide and current hospitalizations have increased by nearly 10% since the beginning of the month.

The U.S. is now averaging nearly 2,400 new coronavirus related deaths a day -- 2,379 to be exact -- which surpasses the country's previous peak in April.

This week alone, 16,653 COVID-19 related deaths were recorded which is nearly 100 American deaths reported every hour.

Additionally, according to data collected by Johns Hopkins University, Friday marked the U.S. highest single-day new case total, with 231,775 new cases.

ABC News' Ahmad Hemingway contributed to this report.

The chief science adviser to Operation Warp Speed, the U.S. government's initiative to expedite vaccine development, said he doesn't know what vaccine-related executive order President Donald Trump is expected to sign on Tuesday.

"Frankly, I don't know and, frankly, I'm staying out of this. I can't comment," Dr. Moncef Slaoui told ABC News chief anchor George Stephanopoulos in an interview Tuesday on "Good Morning America."

When pressed on the matter, Slaoui added: "Our work is, you know, rolling. We have plans. We feel that we can deliver the vaccines as needed, so I don't exactly [know] what this order is about."

Trump is expected to discuss the order at a COVID-19 vaccine summit to be held at the White House later Tuesday, multiple White House officials told reporters during a background briefing on Monday evening. While it's not entirely clear on how exactly the order would work, the move is designed to prevent the U.S. government from shipping any vaccine doses it has purchased to aid foreign countries until all the needs within the United States are met.

White House officials also denied reports that the Trump administration turned down an offer last summer to purchase an additional 400 million doses of a COVID-19 vaccine developed by U.S. pharmaceutical giant Pfizer and its German partner BioNTech, and that the companies now may not be able to provide more of their vaccine to the United States until June 2021 because they have committed those doses to other countries.

When asked about the matter, Slaoui explained Operation Warp Speed's strategy in securing vaccine doses.

"We selected six different vaccines to build a portfolio to manage the risk that some may work and some may not work, but also to ensure that as more than one would work that we would accumulate vaccine doses from this portfolio of vaccines," he said. "If somebody came to us and said, let's buy more of this vaccine or that vaccine, no one reasonably would buy more from any one of those vaccines because we didn't know which one would work and which one may be better than the other. Once the vaccine's performance becomes known is the right time, given the strategy we've taken, to go and order more vaccine doses, which we may be doing. And frankly, the constructive thing to do if one of the suppliers has challenges producing enough vaccine doses is to roll our sleeves and help ensure that capacity can be increased."

Slaoui said he's confident the U.S. government will be getting vaccines to Americans who need them "as soon as possible" and that plans are "still on track."

"We will work with Pfizer to try and increase capacity and have those vaccines available," he said. "We have two more vaccines from J&J and AstraZeneca that will be completing their Phase 3 trials in January and most likely, I hope, be approved for use in February. We have tens of millions of doses from those vaccines, you know, participating to the volume of vaccines we need to immunize the U.S. population as we promised, all of it by the middle of the year 2021 and that's still on track."

Slaoui said Operation Warp Speed has a meeting with President-elect Joe Biden's transition team scheduled for Thursday.

"We look forward to, you know, sharing all the information and working together," he said. "Our objective has always been outside of politics and making sure we make available these vaccines for the U.S. people, and that's what we're doing."

ABC News' Ben Gittleson, John Parkinson and Eric Strauss contributed to this report.